Key Takeaways from the Invasive Aspergillosis Market Report<\/b><\/p>\n Discover which invasive aspergillosis medications are expected to grab the market share @ Invasive Aspergillosis Market Report<\/b><\/a><\/p>\n Invasive Aspergillosis Overview<\/b><\/p>\n Aspergillosis refers to a group of diseases caused by the Aspergillus mold, primarily targeting the lungs. The most common disease-causing species include Aspergillus fumigatus, A. flavus, A. niger, and A. terreus.<\/p>\n There are three main types of aspergillosis. Allergic Bronchopulmonary Aspergillosis (ABPA) occurs in individuals with asthma or cystic fibrosis, leading to allergic inflammation in the lungs. Chronic Pulmonary Aspergillosis (CPA) arises in patients with pre-existing lung conditions and causes progressive lung damage over time. Invasive Aspergillosis, a severe and potentially fatal form, affects immunocompromised individuals as the fungus can spread beyond the lungs to other organs.<\/p>\n Diagnosis of aspergillosis involves a combination of imaging and laboratory tests. CT scans are used to detect lung abnormalities, while fungal cultures help identify the pathogen. PCR testing enables early detection of Aspergillus DNA, and blood-based assays such as galactomannan and \u03b2-D-glucan serve as specific, rapid indicators of invasive infection.<\/p>\n Invasive Aspergillosis Epidemiology Segmentation<\/b><\/p>\n The invasive aspergillosis epidemiology section provides insights into the historical and current invasive aspergillosis patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.<\/p>\n The invasive aspergillosis market report<\/b><\/a> proffers epidemiological analysis for the study period 2020\u20132034 in the 7MM segmented into:<\/p>\n Download the report to understand which factors are driving invasive aspergillosis epidemiology trends @ Invasive Aspergillosis Treatment Algorithm<\/b><\/a><\/p>\n Invasive Aspergillosis Treatment Market\u00a0<\/b><\/p>\n Approaches for aspergillosis treatment include antifungal medications<\/b> such as azoles like voriconazole<\/b>, which serve as first-line therapy, with isavuconazole or posaconazole<\/b> as alternatives; these drugs inhibit fungal growth but may cause liver toxicity and drug interactions. For severe or azole-resistant cases, liposomal amphotericin B is used, while echinocandins act as salvage therapy or are combined with azoles for refractory infections.\u00a0<\/p>\n Corticosteroids<\/b> are primarily employed in allergic bronchopulmonary aspergillosis (ABPA) to reduce inflammation and are often combined with itraconazole to minimize steroid dosage and improve lung function. Surgery <\/b>is recommended for aspergillomas causing significant bleeding or complications, as antifungal medications alone are often ineffective in such cases.\u00a0<\/p>\n Embolization <\/b>provides a temporary solution to control bleeding caused by aspergillomas by blocking the blood supply to the affected area. Immunotherapy <\/b>is emerging as a potential adjunct for invasive aspergillosis, leveraging immune-modulating therapies to enhance host defenses, with early research showing promise.<\/p>\n Learn more about the invasive aspergillosis treatment options @ Invasive Aspergillosis Treatment Guidelines<\/b><\/a><\/p>\n Invasive Aspergillosis Emerging Drugs and Companies<\/b><\/p>\n Key pharmaceutical players for invasive aspergillosis are F2G, Pulmocide, Regeneron, Scynexis<\/b>, and others. The launch of Olorofim (F901318), Opelconazole (PC945), Ibrexafungerp,<\/b> and others is expected to bring forth new treatment options to invasive aspergillosis patients, significantly boosting the growth in the aspergillosis market size.\u00a0<\/p>\n F2G<\/b> is advancing the development of Olorofim (formerly F901318)<\/b>, a first-in-class antifungal designed to address the high mortality rates and drug resistance associated with invasive fungal infections. Olorofim belongs to a new class of antifungal agents and works by inhibiting dihydroorotate dehydrogenase, an enzyme essential for de novo pyrimidine synthesis\u2014a mechanism distinct from existing antifungal treatments.<\/p>\n Olorofim made history as the first antifungal to receive Breakthrough Therapy designation from the FDA in November 2019 and was previously granted Orphan Drug status by the European Commission in October 2016. F2G has partnered with Shionogi, granting them exclusive commercialization rights for Olorofim in Europe and Asia. Currently, the drug is being tested in a Phase III clinical trial, which is in the recruitment phase and expected to conclude by September 2025.<\/p>\n Meanwhile, Pulmocide<\/b> is developing PC945<\/b>, a next-generation inhaled triazole targeting pulmonary aspergillosis. The drug inhibits sterol 14\u03b1-demethylase (CYP51A1), a key enzyme in fungal ergosterol biosynthesis, and is formulated to achieve high concentrations in the lungs with limited systemic absorption. PC945 demonstrates 30- to 100-fold greater potency than Voriconazole against Aspergillus fumigatus and is delivered via nebulization at low daily doses (0.5\u20135 mg).<\/p>\n Pulmocide\u2019s pipeline is focused on both treatment and prevention of pulmonary aspergillosis, including an ongoing Phase III trial for invasive disease and a Phase II trial evaluating prophylactic use. Opelconazole has also received multiple regulatory designations from the FDA to support its accelerated development and review, including Orphan Drug, Fast Track, and Qualified Infectious Disease Product (QIDP) statuses<\/b>. Additionally, it holds Orphan Drug Designation<\/b> in the EU.<\/p>\n The anticipated launch of these emerging invasive aspergillosis therapies are poised to transform the invasive aspergillosis market landscape in the coming years. As these cutting-edge invasive aspergillosis therapies continue to mature and gain regulatory approval, they are expected to reshape the invasive aspergillosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n To know more about new treatment for invasive aspergillosis, visit @ Invasive Aspergillosis Management<\/b><\/a>\u00a0<\/b><\/p>\n Invasive Aspergillosis Market Dynamics<\/b><\/a><\/p>\n The invasive aspergillosis market dynamics are anticipated to change in the coming years. A key strength in managing aspergillosis lies in the use of established diagnostic tools<\/b>, such as serum galactomannan testing, PCR, and CT imaging, that enable earlier and more accurate detection, particularly in immunocompromised patients where timely diagnosis greatly improves outcomes; at the same time, environmental monitoring and infection control measures<\/b>, including HEPA filtration and air quality monitoring during construction, present crucial opportunities to reduce Aspergillus exposure and prevent outbreaks in hospital settings.<\/p>\n Furthermore, many potential therapies are being investigated for the treatment of invasive aspergillosis, and it is safe to predict that the treatment space will significantly impact the invasive aspergillosis market during the forecast period. Moreover, the anticipated introduction of emerging therapies<\/b> with improved efficacy and a further improvement in the diagnosis rate<\/b> is expected to drive the growth of the invasive aspergillosis market in the 7MM.<\/p>\n However, several factors may impede the growth of the invasive aspergillosis market. Invasive aspergillosis carries a high mortality rate<\/b>, particularly in immunocompromised patients, with outcomes remaining poor despite treatment, mortality can exceed 50% in those with hematologic malignancies<\/b>, due to weakened immune defenses, highlighting the need for earlier detection and improved therapies<\/b>; this challenge is further exacerbated by the spread of antifungal resistance<\/b>, driven by the widespread agricultural use of azole-based fungicides<\/b>, which selects for resistant Aspergillus fumigatus strains and undermines the effectiveness of frontline clinical treatments.<\/p>\n Moreover, invasive aspergillosis treatment poses a significant economic burden<\/b> and disrupts patients\u2019 overall well-being and QOL. Furthermore, the invasive aspergillosis market growth may be offset by failures and discontinuation of emerging therapies<\/b>, unaffordable pricing<\/b>, market access and reimbursement issues<\/b>, and a shortage of healthcare specialists<\/b>. In addition, the undiagnosed, unreported cases and the unawareness<\/b> about the disease may also impact the invasive aspergillosis market growth.<\/p>\n Scope of the <\/b>Invasive Aspergillosis<\/b> Market Report<\/b><\/p>\n Discover more about invasive aspergillosis drugs in development @ Invasive Aspergillosis Clinical Trials<\/b><\/a><\/p>\n Table of Contents<\/b><\/p>\n Related Reports<\/b><\/p>\n Invasive Aspergillosis Pipeline<\/b><\/a><\/p>\n Invasive Aspergillosis Pipeline Insight \u2013 2025<\/b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key invasive aspergillosis companies, including F2G, SCYNEXIS, Pulmocide Ltd, TFF Pharmaceuticals, <\/b>among others.<\/p>\n Invasive Aspergillosis Epidemiology Forecast<\/b><\/a><\/p>\n Invasive Aspergillosis Epidemiology Forecast \u2013 2034<\/b> report delivers an in-depth understanding of the disease, historical and forecasted invasive aspergillosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n Aspergillosis Market<\/b><\/a><\/p>\n Aspergillosis Market Insights, Epidemiology, and Market Forecast \u2013 2034 <\/b>report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key aspergillosis companies including Astellas Pharma, Basilea Pharmaceutica International, F2G, Scynexis, Pulmocide,<\/b> among others.<\/p>\n Aspergillosis Pipeline<\/b><\/a><\/p>\n Aspergillosis Pipeline Insight \u2013 2025<\/b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key aspergillosis companies, including Pulmocide, F2G Biotech GmbH, Matinas BioPharma Holdings, Inc, Cipla, Pulmatrix, SCYNEXIS, KBio, <\/b>among others.<\/p>\n Aspergillosis Epidemiology Forecast<\/b><\/a><\/p>\n Aspergillosis Epidemiology Forecast \u2013 2034<\/b> report delivers an in-depth understanding of the disease, historical and forecasted aspergillosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n DelveInsight\u2019s<\/b> Pharma Competitive Intelligence Service<\/b><\/a>: <\/b>Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific\/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.<\/p>\n Other Business Pharmaceutical Consulting Services<\/b><\/p>\n Healthcare Conference Coverage<\/b><\/a><\/p>\n Pipeline Assessment<\/b><\/a><\/p>\n Healthcare Licensing Services<\/b><\/a><\/p>\n Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study<\/b><\/a><\/p>\n About\u00a0DelveInsight<\/b><\/p>\n DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve.<\/b><\/p>\n Connect with us on<\/b> LinkedIn<\/b><\/a>|<\/b>Facebook<\/b><\/a>|<\/b>Twitter<\/b><\/a><\/p>\n\n
![](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/06\/invasive-aspergillosis-market.jpg\" "\\"Invasive-Aspergillosis-Market.jpg\\"")
<\/p>\n\n
\n Invasive Aspergillosis Report Metrics<\/b><\/td>\n Details<\/b><\/td>\n<\/tr>\n \n Study Period<\/td>\n 2020\u20132034<\/td>\n<\/tr>\n \n Invasive Aspergillosis Report Coverage<\/td>\n 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]<\/td>\n<\/tr>\n \n Key Invasive Aspergillosis Companies<\/td>\n F2G, Pulmocide, Regeneron, Scynexis, Astellas Pharma, Basilea Pharmaceutica International, and others<\/td>\n<\/tr>\n \n Key Invasive Aspergillosis Therapies<\/td>\n Olorofim (F901318), Opelconazole (PC945), Ibrexafungerp, CRESEMBA, and others<\/td>\n<\/tr>\n \n
\n 1.<\/td>\n Invasive Aspergillosis Market Key Insights<\/td>\n<\/tr>\n \n 2.<\/td>\n Invasive Aspergillosis Market Report Introduction<\/td>\n<\/tr>\n \n 3.<\/td>\n Invasive Aspergillosis Market Overview at a Glance<\/td>\n<\/tr>\n \n 4.<\/td>\n Invasive Aspergillosis Market Executive Summary<\/td>\n<\/tr>\n \n 5.<\/td>\n Disease Background and Overview<\/td>\n<\/tr>\n \n 6.<\/td>\n Invasive Aspergillosis Treatment and Management<\/td>\n<\/tr>\n \n 7.<\/td>\n Invasive Aspergillosis Epidemiology and Patient Population<\/td>\n<\/tr>\n \n 8.<\/td>\n Patient Journey<\/td>\n<\/tr>\n \n 9.<\/td>\n Invasive Aspergillosis Marketed Drugs<\/td>\n<\/tr>\n \n 10.<\/td>\n Invasive Aspergillosis Emerging Drugs<\/td>\n<\/tr>\n \n 11.<\/td>\n Seven Major Invasive Aspergillosis Market Analysis<\/td>\n<\/tr>\n \n 12.<\/td>\n Invasive Aspergillosis Market Outlook<\/td>\n<\/tr>\n \n 13.<\/td>\n Potential of Current and Emerging Therapies<\/td>\n<\/tr>\n \n 14.<\/td>\n KOL Views<\/td>\n<\/tr>\n \n 15.<\/td>\n Unmet Needs<\/td>\n<\/tr>\n \n 16.<\/td>\n SWOT Analysis<\/td>\n<\/tr>\n \n 17.<\/td>\n Appendix<\/td>\n<\/tr>\n \n 18.<\/td>\n DelveInsight Capabilities<\/td>\n<\/tr>\n \n 19.<\/td>\n Disclaimer<\/td>\n<\/tr>\n \n 20.<\/td>\n About DelveInsight<\/td>\n<\/tr>\n ![\"\"](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/06\/DelveInsight-Business-Research.png\")
<\/p>\n","protected":false},"excerpt":{"rendered":"New York, USA, June 30, 2025 (GLOBE NEWSWIRE) — Invasive Aspergillosis Market Forecast Reveals Opportunities in Antifungal Therapies…\n","protected":false},"author":2,"featured_media":227393,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3091],"tags":[51,89534,89535,89538,89536,89537,2441,16,15],"class_list":{"0":"post-227392","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-business","9":"tag-delveinsight-business-research-llp","10":"tag-invasive-aspergillosis","11":"tag-invasive-aspergillosis-drugs","12":"tag-invasive-aspergillosis-market","13":"tag-invasive-aspergillosis-trials","14":"tag-markets","15":"tag-uk","16":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114774009987127893","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/227392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=227392"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/227392\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/227393"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=227392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=227392"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=227392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}